Akkermansia muciniphila & Metabolic Syndrome (MetS)

Background

Akkermansia muciniphila is a bacterium that has been found to have an inverse relationship with conditions such as adiposity or obesity, ulcerative colitis, and Crohn’s disease. Studies have shown that treatment with A. muciniphila can reverse metabolic disorders induced by a high-fat diet. These disorders include the gain of fat mass, metabolic endotoxemia, inflammation of adipose tissue, and insulin resistance.
Belizário & Faintuch 2018 In: Silvestre, R., Torrado, E. (eds) Metabolic Interaction in Infection. Experientia Supplementum 109 Springer, Cham. https://doi.org/10.1007/978-3-319-74932-7_13
Everard et al. 2013 Proc. Natl. Acad. Sci. USA 110: 9066-9071

In a study conducted by Everard and colleagues, the effects of administering viable Akkermansia muciniphila were compared to those of Akkermansia muciniphila inactivated. The researchers discovered that viable A. muciniphila was effective in normalizing metabolic endotoxemia, which was induced by diet, as well as in regulating fat storage, adipose tissue metabolism, and the CD11c adipose tissue marker. Additionally, treatment with A. muciniphila led to a reduction in body weight and an improvement in body composition, all without altering food intake. Interestingly, these beneficial effects were not observed when Akkermansia muciniphila inactivated was administered.
Everard et al. 2013 Proc. Natl. Acad. Sci. USA 110: 9066-9071

Clinical Data

• NCT05114018 - Akkermansia muciniphila MucT TM & Metabolic syndrome (MetS)

For this randomized clinical treatment trial, no published results could be found as of March 2026

• NCT02637115 - Microbes4U - Akkermansia muciniphila vs Akkermansia muciniphila (killed) vs placebo & Metabolic Syndrome (MetS)

This randomized clinical basic science trial revealed that the intervention was safe and well-tolerated. Additionally, supplementation with Akkermansia muciniphila improves several metabolic parameters. Pasteurization (70°C for 30 min) exposes beneficial outer membrane proteins without viability issues, potentially explaining enhanced efficacy in metabolic parameters.
Depommier et al. 2019 Nat Med. 25(7): 1096-1103

see also:
Akkermansia muciniphila & Type 2 Diabetes (T2D)
Akkermansia muciniphila inactivated & Metabolic syndrome (MetS)
Metabolic Syndrome (MetS) & Drugs/Treatments
Probiotics (living agents) & Metabolic Syndrome (MetS)